Phase III Data to be Presented at American College of Rheumatology Annual Meeting Further Demonstrate Efficacy and Safety of Savella for the Management of Fibromyalgia NEW YORK & SAN DIEGO– –Forest Laboratories, Inc.
Read full story
- Forest Laboratories, Inc. And Cypress Bioscience, Inc. Announce Positive Results Of Phase III Study Of Milnacipran For … (Medical News Today)
Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) announced positive...
- Forest Laboratories, Inc. And Cypress Bioscience, Inc. Announce Commercial Availability Of Savella (BioresearchOnline)
Forest Laboratories, Inc. (NYSE: FRX ) and Cypress Bioscience, Inc. (Nasdaq: CYPB ) announced today ...
- Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for … (PR Newswire via Yahoo! Finance)
Forest Laboratories, Inc. and Cypress Bioscience, Inc. today announced positive top-line results fr...
- Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of … (PR Newswire via Yahoo! Finance)
- Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM) (PR Newswire via Yahoo! Finance)
Category: 
18 October 2009
Sorry, no comments yet.